Clinical trial CANFOUR
An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors
Cancers | |
---|---|
Organ | Multiple |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 1/2 |
Academic trial | Non |
Sponsor | Cantargia AB |
EudraCT Identifier | 2017-001111-36 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03267316 |
Inclusion criteria | Metastatic |
Last update |